KRAS and neoplasm: Furthermore, the broad antitumor activity across different tumor types with KRAS WT amplifications shown here in in vitro and in vivo preclinical models indicates the opportunity for a tumor agnostic approach of targeting KRAS WT–amplified tumors with our current clinical compound BI 3706674.